The three-stage clinical effect of targeted drugs for Roche lung cancer is better than that of chemotherapy

Source: Roche, a famous pharmaceutical company of sina pharmaceutical, announced today that its phase 3 clinical trial Alur reached the main clinical end point, confirming that compared with chemotherapy, alecensa ® (alectinib) It can significantly improve the progression free survival (PFS) of advanced non-small cell lung cancer (NSCLC) patients who have been treated with platinum chemotherapy and crizotinib ALK positive NSCLC is a kind of lung cancer, which is common in young patients (age median 52 years old), female patients (about 54%) and patients with mild or non-smoking Every year, about 75000 people in the world are diagnosed with ALK positive NSCLC Alecensa is an oral ALK inhibitor for patients with ALK positive NSCLC Alur (nct02604342) is a randomized, multicenter, open label, three-phase clinical study to evaluate the efficacy and safety of alecensa in comparison with chemotherapy in patients with ALK positive NSCLC who have received platinum chemotherapy and crizobinib treatment A total of 119 patients were recruited from 15 countries and randomly assigned to receive alecensa treatment or chemotherapy in a ratio of 2:1 The primary end point was progression free survival (PFS), the secondary end point was total survival (OS) and objective response rate (ORR) of central nervous system (CNS) in patients with brain metastasis The other two phase 2 clinical studies (np28673 and np28761) showed that 52.2% of the patients with advanced ALK positive NSCLC had a smaller tumor size and a longer progression free survival to the median of 8.2 and 8.9 months after alecensa treatment In addition, of the patients with CNS metastasis, 64% had CNS tumor reduction after alecensa treatment, and 22% had complete remission Based on this excellent result, alecensa has obtained the conditional marketing authorization from the European Commission for the treatment of ALK positive NSCLC patients treated by crizobinib In addition, alecensa, as a single drug, has been approved by 9 countries and regions, including the United States, for the treatment of advanced ALK positive NSCLC patients who have progressed or are intolerant of crizotinib treatment Another phase 3 clinical trial, Alex, is evaluating alecensa as a first-line option for the treatment of ALK positive NSCLC patients, and the results are expected to be published in the first half of this year "We are pleased to announce that the results of the phase 3 clinical trial Alur further support alecensa's use in the treatment of ALK positive lung cancer patients who have progressed after chemotherapy and crizotinib treatment, and they need updated treatment options," said Sandra, Roche's chief medical officer and global product development director "The results of this trial will support our discussions with the global health sector to bring alecensa to patients faster," Dr horning said (BIOON Com)